{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-133192","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.745754+00:00","generated_at":"2026-06-16T01:08:46.497290+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Life Sciences Q1 net loss narrows to $27.4M; cash $207.6M, pipeline advances with RNA editing candidate toward CTA","bullets":["Q1 revenue $12.9M from GSK/Takeda collaborations vs $1.8M a year ago; net loss $27.4M vs $37.8M.","Cash $207.6M at March 31, 2023 (up from $88.5M Dec 2022) provides runway into 2025, plus potential GSK milestones.","WVE-006, first-in-class RNA editing candidate for AATD, on track for CTA submissions in 2H 2023.","WVE-N531 for DMD: potentially registrational Phase 2 trial to start 2023 with dystrophin primary endpoint; data expected 2024.","WVE-003 HD data delayed to 2H 2023 due to cyber attack at assay vendor; no Wave data compromised."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-133192","json":"https://secwatch.observer/filing/0001193125-23-133192.json","markdown":"https://secwatch.observer/filing/0001193125-23-133192.md","text":"https://secwatch.observer/filing/0001193125-23-133192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523133192/0001193125-23-133192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523133192/d42603d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:08:46.497290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c14e4cf3039369d880871678565b4e635fbe2f3","claim":"Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 3, 2023, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523133192/0001193125-23-133192-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}